IP Library Granted Patent US 9,017,665
Granted Patent B2
US 9,017,665 · App. 13/926,822 · Granted Apr 28, 2015

Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same

Inventor: Joan M. Fallon (Bronxville, NY)
Assignee: Curemark, LLC
A61K38/54A61K38/47A61K38/465A61K38/4826A61K38/4873
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,017,665
App. No.
13/926,822
Granted
Apr 28, 2015
Kind
B2
Abstract

A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.

Claims (12)

1. A method for treating an individual exhibiting one or more symptoms of drug or alcohol addiction, the method comprising administering a therapeutically effective amount of a pharmaceutical preparation comprising digestive enzymes to the individual, whereby the one or more symptoms of drug or alcohol addiction are treated.

2. The method of claim 1 , wherein the digestive enzymes comprise amylase, lipase, and protease.

3. The method of claim 1 , wherein the digestive enzymes consist of amylase, lipase and protease.

4. The method of claim 1 , wherein the digestive enzymes are derived from a source selected from the group consisting of animal enzymes, plant enzymes, synthetic enzymes, and a combination thereof.

5. The method of claim 1 wherein the pharmaceutical preparation is manufactured using a technology selected from the group consisting of enteric coating, lipid encapsulation, direct compression, dry granulation, wet granulation, and a combination thereof.

6. The method of claim 1 , wherein the pharmaceutical preparation is administered orally via a dosage formulation selected from the group consisting of: pills, tablets, capsules, microcapsules, mini-capsules, time released capsules, mini-tabs, sprinkles, and a combination thereof.

7. The method of claim 2 , wherein the amount of amylase ranges from 10,000 to 60,000 USP units/dose.

8. The method of claim 2 , wherein the amount of protease ranges from 10,000 to 70,000 USP units/dose.

9. The method of claim 2 , wherein the amount of lipase ranges from 4,000 to 30,000 USP units/dose.

10. The method of claim 1 , wherein the one or more symptoms of alcohol addiction are treated.

11. The method of claim 1 wherein the one or more symptoms of drug or alcohol addiction are selected from the group consisting of: a lack of protein digestion, a lack of nutrient adsorption, and a combination thereof.

12. The method of claim 1 , wherein the one or more symptoms of drug addiction are treated.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2013
From: FALLON, JOAN M.
To: CUREMARK, LLC
Reel/Frame 031128/0952 →
Continuity (5)
Continuation 13562999 · Jul 31, 2012
Continuation 13271783 · Oct 12, 2011
Continuation 12426794 · Apr 20, 2009
Provisional Application 61046026 · Apr 18, 2008
Related Publication 20140161787A1 · Jun 12, 2014